Our Executive Team
With hundreds of years in combined research, drug development, & business management, our team is dedicated to accelerating wellness by producing the highest quality medicines that introduce global impact, positive outcomes, and deliver hope to those suffering from disease without answers. Join our movement!
Jeffrey B. Halverson
Chief Financial Officer
James Ervin, Ph.D.
Chief Technology Officer
James Carlson, Pharm.D.
Executive VP of Development
Our Advisory Board
BA MB BChir MA MChir FRCS (Gen. Surg.) FRACS (Vascular Surgery)
Dr. Jürgen Lüders is currently employed at Saint Mary’s Mercy Health Neurosurgeon with a specialty in complex spine, epilepsy surgery and brain tumors.
Professor Michael Davies has pioneered studies on the formation and subsequent reactions of oxidants and other reactive species with proteins, DNA and carbohydrates, and the role of such reactions in biological damage. His work on protein modification and the detection and reactions of reactive intermediates is recognized nationally and internationally and has resulted in a number of significant awards.
Conjoint Professor at the School of Medical Sciences Faculty of Medicine University of New South Wales Sydney, Professor Philip Barter has over 200 publications within the medical field.
Dr. Kowalski is board certified by the American Board of Neurological Surgery and is a Fellow of both the American Association of Neurological Surgeons and the American College of Surgeons. His practice encompasses all aspects of cranial and spinal surgery with particular emphasis on motion preservation technologies, minimally invasive surgery (MIS) techniques, and spinal instrumentation.